Skip to main content

Vincent Bruno: Transcriptomics and Fungal Pathogenesis

Premium

Recommended by: Claire Fraser-Liggett, University of Maryland

Vincent Bruno became interested in the molecular aspects of fungal pathogenesis during the first year of his graduate studies. As a PhD student, Bruno worked to generate mutants in Candida albicans in a high-throughput manner. "This was an awful lot of fun because we made several really interesting connections that would not have been made — or would have taken way longer — using a step-by-step scientific method," he says.

Now an assistant professor at the University of Maryland School of Medicine's Institute for Genome Sciences, Bruno is using transcriptomics and other approaches to chip away at "the ability of C. albicans to cause disease," he says. "My work has the potential to identify novel drug targets."

Bruno credits his PhD advisor, Carnegie Mellon University's Aaron Mitchell, with teaching him to always "look where the light is not shining," he says. "The potential of having to delve into a brand-new area within a field is what keeps me excited about using genomics and functional genomics to study biological problems."

Publication of note

Among his publications, Bruno considers a 2010 Genome Research paper in which he and his colleagues mapped the C. albicans transcriptome using RNA-seq as particularly influential. "We identified about 600 new genes that were not previously known," Bruno says.

Looking ahead

In the next five to 10 years, Bruno says he expects researchers to have maxed out their efforts to deep-sequence microorganisms. Then, he adds, "there will be a real push to transform all the sequencing data into functional, biologically useful information."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.